US Stock MarketDetailed Quotes

MTSR Metsera

Watchlist
  • 23.300
  • +3.490+17.62%
Close Apr 29 16:00 ET
2.45BMarket Cap-11.70P/E (TTM)

About Metsera Company

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Company Profile

SymbolMTSR
Company NameMetsera
Listing DateJan 31, 2025
Issue Price18.00
Founded2022
CEOMr. Christopher Whitten Bernard
MarketNASDAQ
Employees81
Fiscal Year Ends12-31
Address3 World Trade Center,175 Greenwich Street
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10007
Phone1-212-784-6595

Company Executives

  • Name
  • Position
  • Salary
  • Christopher Whitten Bernard
  • President, Chief Executive Officer and Director
  • 5.73M
  • Christopher J. Visioli
  • Chief Business Officer and Chief Financial Officer
  • 2.85M
  • Dr. Steven Marso, M.D.
  • Chief Medical Officer
  • --
  • Dr. Brian Hubbard, Pd.D
  • Chief Scientific Officer
  • 1.02M
  • Gbola Amusa, M.D.
  • Executive Vice President, Strategic Finance and Investor Relations
  • 1.62M
  • Dr. Clive A. Meanwell, M.D.,PhD
  • Executive Chairman of the Board
  • 1.80M
  • Jon P. Stonehouse
  • Director
  • --
  • Kristina M. Burow
  • Independent Director
  • 849.99K
  • Paul L. Berns
  • Independent Director
  • 1.27M
  • Dr. Joshua Pinto, PhD
  • Independent Director
  • 445.75K

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Unlock Now

Discussing

Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks Show More